Open App →
Back to News Feed
PR Newswire November 19, 2026 neutral

Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs

AI / LLM
<p>Company advances its internally developed drug discovery program targeting acute graft-versus-host disease (aGVHD) and AgPlenus' fungicide discovery programs targeting novel MoA against Septoria REHOVOT, Israel, Nov. 19, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a...</p>
Read original article ↗

Related Articles

New Taipei City candidate released on bail

Taipei Times · November 20, 2026

Taipei certifies Japanese-era artifacts from schools

Taipei Times · November 20, 2026

Trump unlikely to concede on Taiwan: academics

Taipei Times · November 20, 2026

Two damaged Taichung MRT cars to be auctioned off

Taipei Times · November 20, 2026